Avalo Therapeutics, Inc. (AVTX)Healthcare | Biotechnology | Wayne, United States | NasdaqCM
14.29 USD
-0.37
(-2.524%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 19, 2026, 1:37 a.m. EDT
Avalo Therapeutics is exhibiting the classic 'biotech gamble' profile: deep technical distress balanced against aggressive institutional speculation on next-generation product data. The 240% drop from its 2023 highs and negative fundamentals make it a terrible permanent hold, but the options data screams 'momentum play' with speculative buyers betting all-in on a potential catalyst-driven rebound to avoid deep strikes. This is a binary event-driven trade, not an investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.080871 |
| AutoTheta | 0.082146 |
| AutoETS | 0.082305 |
| AutoARIMA | 0.104199 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 60% |
| H-stat | 1.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.391 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.514 |
| Revenue per Share | 0.004 |
| Market Cap | 325,646,976 |
| Forward P/E | -4.71 |
| Beta | 0.94 |
| Previous Name | Cerecor Inc. |
| Website | https://www.avalotx.com |
As of April 19, 2026, 1:37 a.m. EDT: Options flow shows aggressive call buying with disproportionate Open Interest (OI) at strikes 22.5 (100+ contracts OI) and 30.0 (10k OI) for May and June expirations, suggesting a high-strike momentum target. Conversely, put activity is concentrated at deep strikes (10.0, strike 10 for May/June) with significant OI, indicating a defined downside risk zone near the technical lows. The put/call ratio is skewed towards calls in terms of directional bias, though overall volume suggests a high-risk/high-reward speculative setup rather than a stable accumulation phase.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8868687 |
| Address1 | 1,500 Liberty Ridge Drive |
| Address2 | Suite 321 |
| All Time High | 22,032.0 |
| All Time Low | 3.39 |
| Ask | 18.18 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 789,070 |
| Average Daily Volume3 Month | 668,632 |
| Average Volume | 668,632 |
| Average Volume10Days | 789,070 |
| Beta | 0.944 |
| Bid | 10.45 |
| Bid Size | 2 |
| Book Value | 4.486 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.29 |
| Current Ratio | 8.136 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.75 |
| Day Low | 14.12 |
| Debt To Equity | 0.514 |
| Display Name | Avalo Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -72,581,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.138 |
| Enterprise To Revenue | 3,859.966 |
| Enterprise Value | 227,737,984 |
| Eps Current Year | -3.23667 |
| Eps Forward | -3.03333 |
| Eps Trailing Twelve Months | -5.84 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.3488 |
| Fifty Day Average Change | -1.0587997 |
| Fifty Day Average Change Percent | -0.06898258 |
| Fifty Two Week Change Percent | 188.68687 |
| Fifty Two Week High | 20.72 |
| Fifty Two Week High Change | -6.4299994 |
| Fifty Two Week High Change Percent | -0.31032816 |
| Fifty Two Week Low | 3.39 |
| Fifty Two Week Low Change | 10.9 |
| Fifty Two Week Low Change Percent | 3.215339 |
| Fifty Two Week Range | 3.39 - 20.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,444,829,400,000 |
| Float Shares | 20,144,536 |
| Forward Eps | -3.03333 |
| Forward P E | -4.7109942 |
| Free Cashflow | -17,263,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -35,287,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02577 |
| Held Percent Institutions | 0.84669 |
| Implied Shares Outstanding | 22,788,452 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,703,808,000 |
| Last Split Factor | 1:240 |
| Long Business Summary | Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania. |
| Long Name | Avalo Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 325,646,976 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_145313032 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -78,259,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 325,874,863 |
| Number Of Analyst Opinions | 11 |
| Open | 14.75 |
| Operating Cashflow | -51,458,000 |
| Operating Margins | -334.61017 |
| Payout Ratio | 0.0 |
| Phone | 410 522 8707 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 14.29 |
| Pre Market Time | 1,776,844,806 |
| Prev Name | Cerecor Inc. |
| Previous Close | 14.66 |
| Price Eps Current Year | -4.4150314 |
| Price Hint | 2 |
| Price To Book | 3.1854658 |
| Price To Sales Trailing12 Months | 5,519.4404 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.599 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | -0.37 |
| Regular Market Change Percent | -2.52387 |
| Regular Market Day High | 14.75 |
| Regular Market Day Low | 14.12 |
| Regular Market Day Range | 14.12 - 14.75 |
| Regular Market Open | 14.75 |
| Regular Market Previous Close | 14.66 |
| Regular Market Price | 14.29 |
| Regular Market Time | 1,776,801,601 |
| Regular Market Volume | 674,422 |
| Return On Assets | -0.34117 |
| Return On Equity | -0.72435 |
| Revenue Growth | -0.693 |
| Revenue Per Share | 0.004 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 22,788,452 |
| Shares Percent Shares Out | 0.2432 |
| Shares Short | 5,542,400 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,681,926 |
| Short Name | Avalo Therapeutics, Inc. |
| Short Percent Of Float | 0.2441 |
| Short Ratio | 6.85 |
| Source Interval | 15 |
| State | PA |
| Symbol | AVTX |
| Target High Price | 52.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 40.09091 |
| Target Median Price | 40.0 |
| Total Cash | 98,336,000 |
| Total Cash Per Share | 4.315 |
| Total Debt | 427,000 |
| Total Revenue | 59,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.84 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.8845 |
| Two Hundred Day Average Change | 0.4055004 |
| Two Hundred Day Average Change Percent | 0.029205259 |
| Type Disp | Equity |
| Volume | 674,422 |
| Website | https://www.avalotx.com |
| Zip | 19,087 |